JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral ...
InflaRx was founded in 2007 and maintains offices in Jena and Munich, Germany, and Ann Arbor, Michigan. In other recent news, InflaRx N.V. has disclosed post-hoc analyses indicating potential efficacy ...
Dr. Clarissa Souza, a board-certified veterinary dermatologist and head of the dermatology and otology service at the University of Illinois Veterinary Teaching Hospital in Urbana. Dr. Clarissa Souza, ...
A multidisciplinary panel of medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, neurology, hematology, emergency medicine ...
A Prescription Drug User Fee Act target date of December 12, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...
InflaRx N.V. (NASDAQ: IFRX) is reviving hopes for vilobelimab after new analyses showed signs of efficacy in a Phase 3 trial it had previously halted, setting up FDA talks and a potential partner-led ...
Although it looked to be lights out for InflaRx’s C5a antibody vilobelimab in the rare skin disorder pyoderma gangrenosum (PG) last year, the German drugmaker ended 2025 with a glimmer of hope for the ...
1 Department of Cardio Thoracic and Vascular Surgery, All India Institute of Medical Sciences, Raipur, India. 2 Department of Cardio Thoracic and Vascular Surgery, Sri Padmavathi Children’s Heart ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results